|
1
|
Guzik A and Bushnell C: Stroke
epidemiology and risk factor management. Continuum (Minneap Minn).
23:15–39. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Randolph SA: Ischemic stroke. Workplace
Health Saf. 64(444)2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sreedharan R and Abdelmalak B: Diabetes
mellitus: Preoperative concerns and evaluation. Anesthesiol Clin.
36:581–597. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Echouffo-Tcheugui JB and Garg R:
Management of hyperglycemia and diabetes in the emergency
department. Curr Diab Rep. 17(56)2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Hill MD: Stroke and diabetes mellitus.
Handb Clin Neurol. 126:167–174. 2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Shindo A and Tomimoto H: Diabetes and
ischemic stroke. Brain Nerve. 66:107–119. 2014.PubMed/NCBI(In Japanese).
|
|
7
|
Chen R, Ovbiagele B and Feng W: Diabetes
and stroke: Epidemiology, pathophysiology, pharmaceuticals and
outcomes. Am J Med Sci. 351:380–386. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Campos AC, Fogaca MV, Sonego AB and
Guimaraes FS: Cannabidiol, neuroprotection and neuropsychiatric
disorders. Pharmacol Res. 112:119–127. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lavaur J, Le Nogue D, Lemaire M, Pype J,
Farjot G, Hirsch EC and Michel PP: The noble gas xenon provides
protection and trophic stimulation to midbrain dopamine neurons. J
Neurochem. 142:14–28. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Lavaur J, Lemaire M, Pype J, Nogue DL,
Hirsch EC and Michel PP: Xenon-Mediated neuroprotection in response
to sustained, low-level excitotoxic stress. Cell Death Discov.
2(16018)2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bernstock JD, Peruzzotti-Jametti L, Ye D,
Gessler FA, Maric D, Vicario N, Lee YJ, Pluchino S and Hallenbeck
JM: Neural stem cell transplantation in ischemic stroke: A role for
preconditioning and cellular engineering. J Cereb Blood Flow Metab.
37:2314–2319. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Boncoraglio GB, Ranieri M, Bersano A,
Parati EA and Del Giovane C: Stem cell transplantation for ischemic
stroke. Cochrane Database Syst Rev. 5(CD007231)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Chong MS, Ng WK and Chan JK: Concise
review: Endothelial progenitor cells in regenerative medicine:
Applications and challenges. Stem Cells Transl Med. 5:530–538.
2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yang JX, Pan YY, Wang XX, Qiu YG and Mao
W: Endothelial progenitor cells in age-related vascular remodeling.
Cell Transplant. 27:786–795. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Emontzpohl C, Simons D, Kraemer S,
Goetzenich A, Marx G, Bernhagen J and Stoppe C: Isolation of
endothelial progenitor cells from healthy volunteers and their
migratory potential influenced by serum samples after cardiac
surgery. J Vis Exp. 14(55192)2017.PubMed/NCBI View
Article : Google Scholar
|
|
16
|
Guerra G, Perrotta F and Testa G:
Circulating endothelial progenitor cells biology and regenerative
medicine in pulmonary vascular diseases. Curr Pharm Biotechnol.
19:700–707. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rana D, Kumar A and Sharma S: Endothelial
progenitor cells as molecular targets in vascular senescence and
repair. Curr Stem Cell Res Ther. 13:438–446. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Esquiva G, Grayston A and Rosell A:
Revascularization and endothelial progenitor cells in stroke. Am J
Physiol Cell Physiol. 315:C664–C674. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Li Y, Chang S, Li W, Tang G, Ma Y, Liu Y,
Yuan F, Zhang Z, Yang GY and Wang Y: cxcl12-Engineered endothelial
progenitor cells enhance neurogenesis and angiogenesis after
ischemic brain injury in mice. Stem Cell Res Ther.
9(139)2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ma F, Morancho A, Montaner J and Rosell A:
Endothelial progenitor cells and revascularization following
stroke. Brain Res. 1623:150–159. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Jablonska-Trypuc A, Matejczyk M and
Rosochacki S: Matrix metalloproteinases (MMPs), the main
extracellular matrix (ECM) enzymes in collagen degradation, as a
target for anticancer drugs. J Enzyme Inhib Med Chem. 31:177–183.
2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Omran OM and Thabet M: Gelatinases a and B
expression in human colorectal cancer in upper egypt: A
clinicopathological study. Ultrastruct Pathol. 36:108–116.
2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Cui N, Hu M and Khalil RA: Biochemical and
biological attributes of matrix metalloproteinases. Prog Mol Biol
Transl Sci. 147:1–73. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Back M, Ketelhuth DF and Agewall S: Matrix
metalloproteinases in atherothrombosis. Prog Cardiovasc Dis.
52:410–428. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lin HF, His E, Huang LC, Liao YC, Juo SH
and Lin RT: Methylation in the matrix metalloproteinase-2 gene is
associated with cerebral ischemic stroke. J Investig Med.
65:794–799. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Palm F, Pussinen PJ, Safer A,
Tervahartiala T, Sorsa T, Urbanek C, Becher H and Grau AJ: Serum
matrix metalloproteinase-8, tissue inhibitor of metalloproteinase
and myeloperoxidase in ischemic stroke. Atherosclerosis. 271:9–14.
2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Chaturvedi M and Kaczmarek L: Mmp-9
inhibition: A therapeutic strategy in ischemic stroke. Mol
Neurobiol. 49:563–573. 2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tasca CI, Dal-Cim T and Cimarosti H: In
vitro oxygen-glucose deprivation to study ischemic cell death.
Methods Mol Biol. 125:197–210. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Liang X, Liu X, Lu F, Zhang Y, Jiang X and
Ferriero DM: HIF1α signaling in the endogenous protective responses
after neonatal brain hypoxia-ischemia. Dev Neurosci. 40:617–626.
2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Novak AE, Jones SM and Elliott JP:
Induction of the HIF pathway: Differential regulation by chemical
hypoxia and oxygen glucose deprivation. bioR. xiv(525006)2019.
|
|
31
|
Zhang Y, Liu D, Hu H, Zhang P, Xie R and
Cui W: HIF-1α/BNIP3 signaling pathway-induced-autophagy plays
protective role during myocardial ischemia-reperfusion injury.
Biomed Pharmacother. 120(109464)2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Liu C, Kong X, Wu X, Wang X, Guan H, Wang
H, Wang L, Jin X and Yuan H: Alleviation of A disintegrin and
metalloprotease 10 (ADAM10) on thromboangiitis obliterans involves
the HMGB1/RAGE/ NF-kappaB pathway. Biochem Biophys Res Commun.
505:282–289. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M
and Chopp M: Therapeutic benefit of intravenous administration of
bone marrow stromal cells after cerebral ischemia in rats. Stroke.
32:1005–1011. 2001.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Lee YK and Lee JA: Role of the mammalian
ATG8/LC3 family in autophagy: Differential and compensatory roles
in the spatiotemporal regulation of autophagy. BMB Rep. 49:424–430.
2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Hardigan T, Ward R and Ergul A:
Cerebrovascular complications of diabetes: Focus on cognitive
dysfunction. Clin Sci (Lond). 130:1807–1822. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Khan S, Shafique L and Miah M: Risk
factors and patterns of stroke among diabetic and non-diabetic
patients. Imperial Journal of Interdisciplinary Research 3,
2017.
|
|
37
|
Mohammedi K, Woodward M, Hirakawa Y,
Zoungas S, Williams B, Lisheng L, Rodgers A, Mancia G, Neal B,
Harrap S, et al: Microvascular and macrovascular disease and risk
for major peripheral arterial disease in patients with type 2
diabetes. Diabetes Care. 39:1796–1803. 2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Alloubani A, Saleh A and Abdelhafiz I:
Hypertension and diabetes mellitus as a predictive risk factors for
stroke. Diabetes Metab Syndr. 12:577–584. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Boehme AK, Esenwa C and Elkind MS: Stroke
risk factors, genetics, and prevention. Circ Res. 120:472–495.
2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Rodriguez-Carrio J, Lopez P and Suarez A:
Endothelial progenitor cells as mediators of the crosstalk between
vascular repair and immunity: Lessons from systemic autoimmune
diseases. Curr Med Chem. 25:4478–4496. 2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Lois N, McCarter RV, O'Neill C, Medina RJ
and Stitt AW: Endothelial progenitor cells in diabetic retinopathy.
Front Endocrinol (Lausanne). 5(44)2014.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Shao Y, Li X, Wood JW and Ma JX:
Mitochondrial dysfunctions, endothelial progenitor cells and
diabetic retinopathy. J Diabetes Complications. 32:966–973.
2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Wils J, Favre J and Bellien J: Modulating
putative endothelial progenitor cells for the treatment of
endothelial dysfunction and cardiovascular complications in
diabetes. Pharmacol Ther. 170:98–115. 2017.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Schmeisser A, Garlichs CD, Zhang H, Eskafi
S, Graffy C, Ludwig J, Strasser RH and Daniel WG: Monocytes
coexpress endothelial and macrophagocytic lineage markers and form
cord-like structures in matrigel under angiogenic conditions.
Cardiovasc Res. 49:671–680. 2001.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Peichev M, Naiyer AJ, Pereira D, Zhu Z,
Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA and Rafii
S: Expression of VEGFR-2 and AC133 by circulating human CD34(+)
cells identifies a population of functional endothelial precursors.
Blood. 95:952–958. 2000.PubMed/NCBI
|
|
46
|
Takahashi T, Kalka C, Masuda H, Chen D,
Silver M, Kearney M, Magner M, Isner JM and Asahara T: Ischemia-
and cytokine-induced mobilization of bone marrow-derived
endothelial progenitor cells for neovascularization. Nat Med.
5:434–438. 1999.PubMed/NCBI View
Article : Google Scholar
|
|
47
|
He S, Pant D, Schiffmacher A, Bischoff S,
Melican D, Gavin W and Keefer C: Developmental expression of
pluripotency determining factors in caprine embryos: Novel pattern
of NANOG protein localization in the nucleolus. Mol Reprod Dev.
73:1512–1522. 2006.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Wagner DD, Olmsted JB and Marder VJ:
Immunolocalization of von Willebrand protein in Weibel-Palade
bodies of human endothelial cells. J Cell Biol. 95:355–360.
1982.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Heeschen C, Aicher A, Lehmann R,
Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher
AM and Dimmeler S: Erythropoietin is a potent physiologic stimulus
for endothelial progenitor cell mobilization. Blood. 102:1340–1346.
2003.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Nagase H, Visse R and Murphy G: Structure
and function of matrix metalloproteinases and TIMPs. Cardiovasc
Res. 69:562–573. 2006.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Theocharis AD, Skandalis SS, Gialeli C and
Karamanos NK: Extracellular matrix structure. Adv Drug Deliv Rev.
97:4–27. 2016.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Bonnans C, Chou J and Werb Z: Remodelling
the extracellular matrix in development and disease. Nat Rev Mol
Cell Biol. 15:786–801. 2014.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Paiva KBS and Granjeiro JM: Matrix
metalloproteinases in bone resorption, remodeling, and repair. Prog
Mol Biol Transl Sci. 148:203–303. 2017.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Wei H, Wang S, Zhen L, Yang Q, Wu Z, Lei
X, Lv J, Xiong L and Xue R: Resveratrol attenuates the blood-brain
barrier dysfunction by regulation of the MMP-9/TIMP-1 balance after
cerebral ischemia reperfusion in rats. J Mol Neurosci. 55:872–879.
2015.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Toth M, Sohail A and Fridman R: Assessment
of gelatinases (MMP-2 and MMP-9) by gelatin zymography. Methods Mol
Biol. 878:121–135. 2012.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Dong H, Diao H, Zhao Y, Xu H, Pei S, Gao
J, Wang J, Hussain T, Zhao D, Zhou X and Lin D: Overexpression of
matrix metalloproteinase-9 in breast cancer cell lines remarkably
increases the cell malignancy largely via activation of
transforming growth factor beta/SMAD signalling. Cell Prolif.
52(e12633)2019.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Hongwei Y, Ruiping C, Yingyan F, Guanjun
Z, Jie H, Xingyu L, Jie T, Zhenghong L, Qin G, Junfeng H and Heng
Z: Effect of Irbesartan on AGEs-RAGE and MMPs systems in rat type 2
diabetes myocardial-fibrosis model. Exp Biol Med (Maywood).
244:612–620. 2019.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Song W and Ergul A: Type-2
diabetes-induced changes in vascular extracellular matrix gene
expression: Relation to vessel size. Cardiovasc Diabetol.
5(3)2006.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Nishihama K, Yasuma T, Yano Y,
D'Alessandro-Gabazza CN, Toda M, Hinneh JA, Tonto PB, Takeshita A,
Totoki T, Mifuji-Moroka R, et al: Anti-Apoptotic activity of human
matrix metalloproteinase-2 attenuates diabetes mellitus.
Metabolism. 82:88–99. 2018.PubMed/NCBI View Article : Google Scholar
|
|
60
|
de de Morais EF, Dantas AN, Pinheiro JC,
Leite RB, Barboza CA, de Vasconcelos Gurgel BC and de Almeida
Freitas R: Matrix metalloproteinase-8 analysis in patients with
periodontal disease with prediabetes or type 2 diabetes mellitus: A
systematic review. Arch Oral Biol. 87:43–51. 2018.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Zhong C, Yang J, Xu T, Xu T, Peng Y, Wang
A, Wang J, Peng H, Li Q, Ju Z, et al: Serum matrix
metalloproteinase-9 levels and prognosis of acute ischemic stroke.
Neurology. 89:805–812. 2017.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Abdelnaseer MM, Elfauomy NM, Esmail EH,
Kamal MM and Elsawy EH: Matrix metalloproteinase-9 and recovery of
acute ischemic stroke. J Stroke Cerebrovasc Dis. 26:733–740.
2017.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Fatar M, Stroick M, Steffens M, Senn E,
Reuter B, Bukow S, Griebe M, Alonso A, Lichtner P, Bugert P, et al:
Single-Nucleotide polymorphisms of MMP-2 gene in stroke subtypes.
Cerebrovasc Dis. 26:113–119. 2008.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Nosoudi N, Nahar-Gohad P, Sinha A,
Chowdhury A, Gerard P, Carsten CG, Gray BH and Vyavahare NR:
Prevention of abdominal aortic aneurysm progression by targeted
inhibition of matrix metalloproteinase activity with
batimastat-loaded nanoparticles. Circ Res. 117:e80–e89.
2015.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Walz W and Cayabyab FS: Neutrophil
infiltration and matrix metalloproteinase-9 in lacunar infarction.
Neurochem Res. 42:2560–2565. 2017.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Singh T, Jayaram B and Adekoya OA:
Computational approaches to matrix metalloprotease drug design.
Methods Mol Biol. 1579:273–285. 2017.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Wu Z, Mulatibieke T, Niu M, Li B, Dai J,
Ye X, He Y, Chen C, Wen L and Hu G: Inhibition of matrix
metalloproteinase with BB-94 protects against caerulein-induced
pancreatitis via modulating neutrophil and macrophage activation.
Gastroenterol Res Pract. 28(8903610)2020.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Dong F, Eibach M, Bartsch JW, Dolga AM,
Schlomann U, Conrad C, Schieber S, Schilling O, Biniossek ML,
Culmsee C, et al: The metalloprotease-disintegrin ADAM8 contributes
to temozolomide chemoresistance and enhanced invasiveness of human
glioblastoma cells. Neuro Oncol. 17:1474–1485. 2015.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Gautam J, Banskota S, Lee H, Lee YJ, Jeon
YH, Kim JA and Jeong BS: Down-Regulation of cathepsin S and matrix
metalloproteinase-9 via src, a non-receptor tyrosine kinase,
suppresses triple-negative breast cancer growth and metastasis. Exp
Mol Med. 50:1–14. 2018.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Sledge GW Jr, Qulali M, Goulet R, Bone EA
and Fife R: Effect of matrix metalloproteinase inhibitor batimastat
on breast cancer regrowth and metastasis in athymic mice. J Natl
Cancer Inst. 87:1546–1551. 1995.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Wojtowicz-Praga S, Low J, Marshall J, Ness
E, Dickson R, Barter J, Sale M, McCann P, Moore J, Cole A and
Hawkins MJ: Phase I trial of a novel matrix metalloproteinase
inhibitor batimastat (BB-94) in patients with advanced cancer.
Invest New Drugs. 14:193–202. 1996.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Winer A, Adams S and Mignatti P: Matrix
metalloproteinase inhibitors in cancer therapy: Turning past
failures into future successes. Mol Cancer Ther. 17:1147–1155.
2018.PubMed/NCBI View Article : Google Scholar
|
